Back to News
Latest MHRA Drug Safety Update - March 2019
Posted on 21 Mar 2019
The latest MHRA Drug Safety Update, March 2019
This month article features are:
- information to all healthcare professionals of new restrictions and precautions for use of fluoroquinolone antibiotics following a detailed EU review of very rare reports of disabling and potentially long-lasting or irreversible side effects affecting the musculoskeletal and nervous systems. Healthcare professionals and patients should be vigilant during treatment with fluoroquinolone antibiotics and treatment should be discontinued at the first sign of tendon pain or inflammation (page 2).
- read about serious and fatal thromboembolic events reported in association with liposomal irinotecan (Onivyde), authorised for metastatic adenocarcinoma of the pancreas (page 6). Patients should be informed about the signs and symptoms of thromboembolism and be advised to seek medical advice immediate if any occur.
- prescribers of any medicines with teratogenic potential should download, print, and use the new aide-memoire table, which provides guidance on contraceptive methods and the related frequency of pregnancy testing recommended. See page 8 to the advice and page 10 for the table.